Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Wijenayaka, Asiri R ^a   Kogawa, Masakazu ^a   Lim, Hui Peng ^a   Bonewald, Lynda F ^b   Findlay, David M ^a   Atkins, Gerald J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT PROTEIN; SCLEROSTIN; ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BONE MORPHOGENETIC PROTEIN; ISOENZYME; SOST PROTEIN, HUMAN; TARTRATE-RESISTANT ACID PHOSPHATASE;

APOPTOSIS; ARTICLE; CATABOLISM; CELL COUNT; CELL CULTURE; CELL LINE; CELL SIZE; CELL STRAIN MLO Y4; COCULTURE; CONTROLLED STUDY; ENZYME ASSAY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MONOCULTURE; MULTINUCLEAR CELL; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; SPLEEN CELL; UPREGULATION; ADULT; ANIMAL; BONE DEVELOPMENT; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; GENETIC MARKER; GENETICS; METABOLISM; MOUSE; OSTEOBLAST; OSTEOCLAST; SIGNAL TRANSDUCTION;

ACID PHOSPHATASE; ADULT; ANIMALS; APOPTOSIS; BONE MORPHOGENETIC PROTEINS; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; ISOENZYMES; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; OSTEOGENESIS; RANK LIGAND; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 80053518269     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025900     Document Type: Article

References (64)

1. Baron R, Rawadi G, Roman-Roman S, (2006) Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol 76: 103-127.
2. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, et al. (2008) Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength. J Bone Miner Res 23: 860-869.
3. ten Dijke P, Krause C, de Gorter DJ, Lowik CW, van Bezooijen RL, (2008) Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 90 (Suppl 1): 31-35.
4. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, et al. (2002) Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39: 91-97.
5. Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, et al. (2002) A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 110: 144-152.
6. Padhi D, Jang G, Stouch B, Fang L, Posvar E, (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26: 19-26.
7. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, et al. (2003) Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278: 24113-24117.
8. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, et al. (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. Embo J 22: 6267-6276.
9. Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA, (2004) Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 35: 448-454.
10. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, et al. (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199: 805-814.
11. Winkler DG, Sutherland MS, Ojala E, Turcott E, Geoghegan JC, et al. (2005) Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 280: 2498-2502.
12. Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, et al. (2010) Distinct modes of inhibition by sclerostin on bone morphogenetic protein and wnt signaling pathways. J Biol Chem 285: 41614-41626.
13. Li X, Zhang Y, Kang H, Liu W, Liu P, et al. (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280: 19883-19887.
14. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, et al. (2007) Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22: 19-28.
15. Choi HY, Dieckmann M, Herz J, Niemeier A, (2009) Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE 4: e7930.
16. Leupin O, Piters E, Halleux C, Hu S, Kramer I, et al. (2011) Bone overgrowth-associated mutations in LRP4 impair sclerostin-facilitator function. J Biol Chem 286: 19489-19500.
17. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, et al. (2009) Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 24: 1434-1449.
18. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, et al. (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578-588.
19. Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, et al. (2010) Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 47: 529-533.
20. Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, et al. (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8: 751-764.
21. Kaneuji T, Ariyoshi W, Okinaga T, Toshinaga A, Takahashi T, et al. (2011) Mechanisms involved in regulation of osteoclastic differentiation by mechanical stress-loaded osteoblasts. Biochem Biophys Res Commun 408: 103-109.
22. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, et al. (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Faseb J 19: 1842-1844.
23. Robling AG, Bellido T, Turner CH, (2006) Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact 6: 354.
24. Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, et al. (2007) Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38: 261-269.
25. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, et al. (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146: 4577-4583.
26. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, et al. (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. J Biol Chem 283: 5866-5875.
27. Findlay DM, Atkins GJ, (2011) TWEAK and TNF regulation of sclerostin: a novel pathway for the regulation of bone remodelling. Adv Exp Med Biol 691: 337-348.
28. Ikeda T, Utsuyama M, Hirokawa K, (2001) Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res 16: 1416-1425.
29. Mueller RJ, Richards RG, (2004) Immunohistological identification of receptor activator of NF-kappaB ligand (RANKL) in human, ovine and bovine bone tissues. J Mater Sci Mater Med 15: 367-372.
30. Shiotani A, Shibasaki Y, Sasaki T, (2001) Localization of receptor activator of NFkappaB ligand, RANKL, in periodontal tissues during experimental movement of rat molars. J Electron Microsc (Tokyo) 50: 365-369.
31. Kurata K, Heino TJ, Higaki H, Vaananen HK, (2006) Bone marrow cell differentiation induced by mechanically damaged osteocytes in 3D gel-embedded culture. J Bone Miner Res 21: 616-625.
32. Zhao S, Zhang YK, Harris S, Ahuja SS, Bonewald LF, (2002) MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res 17: 2068-2079.
33. Atkins GJ, Welldon KJ, Halbout P, Findlay DM, (2009) Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20: 653-664.
34. Atkins GJ, Welldon KJ, Holding CA, Haynes DR, Howie DW, et al. (2009) The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials 30: 3672-3681.
35. Atkins GJ, Welldon KJ, Wijenayaka AR, Bonewald LF, Findlay DM, (2009) Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by {gamma}-carboxylation-dependent and-independent mechanisms. Am J Physiol Cell Physiol 297: C1358-1367.
36. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, et al. (2011) Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res 26: 1425-1436.
37. Kato Y, Windle JJ, Koop BA, Mundy GR, Bonewald LF, (1997) Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res 12: 2014-2023.
38. Gronthos S, Zannettino AC, Graves SE, Ohta S, Hay SJ, et al. (1999) Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J Bone Miner Res 14: 47-56.
39. Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, et al. (2003) RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 18: 1088-1098.
40. Kogawa M, Findlay DM, Anderson PH, Ormsby R, Vincent C, et al. (2010) Osteoclastic Metabolism of 25(OH)-Vitamin D3: A Potential Mechanism for Optimization of Bone Resorption. Endocrinology 151: 4613-4625.
41. Atkins GJ, Kostakis P, Vincent C, Farrugia AN, Houchins JP, et al. (2006) RANK Expression as a Cell Surface Marker of Human Osteoclast Precursors in Peripheral Blood, Bone Marrow, and Giant Cell Tumors of Bone. J Bone Miner Res 21: 1339-1349.
42. Atkins GJ, Anderson PH, Findlay DM, Welldon KJ, Vincent C, et al. (2007) Metabolism of vitamin D(3) in human osteoblasts: Evidence for autocrine and paracrine activities of 1alpha,25-dihydroxyvitamin D(3). Bone 40: 1517-1528.
43. Findlay DM, Welldon K, Atkins GJ, Howie DW, Zannettino AC, et al. (2004) The proliferation and phenotypic expression of human osteoblasts on tantalum metal. Biomaterials 25: 2215-2227.
44. Medina V, Edmonds B, Young GP, James R, Appleton S, et al. (1997) Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 57: 3697-3707.
45. Atkins GJ, Bouralexis S, Evdokiou A, Hay S, Labrinidis A, et al. (2002) Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone 31: 448-456.
46. Chan A, van Bezooijen RL, Lowik CW, (2007) A new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists. Curr Opin Investig Drugs 8: 293-298.
47. Rey JP, Ellies DL, (2010) Wnt modulators in the biotech pipeline. Dev Dyn 239: 102-114.
48. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, et al. (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23: 860-869.
49. Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, et al. (2010) Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women. J Clin Endocrinol Metab.
50. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, et al. (2010) Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95: 2248-2253.
51. Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, et al. (2010) Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res.
52. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, et al. (2010) Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 30: 3071-3085.
53. Kramer I, Loots GG, Studer A, Keller H, Kneissel M, (2009) Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25: 178-189.
54. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, et al. (2005) Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15: 928-935.
55. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, et al. Matrix-embedded cells control osteoclast formation. Nat Med (In press). DOI: nm.2448 [pii]2410.1038/nm.2448.
56. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (In press): DOI: nm.2452 [pii]2410.1038/nm.2452.
57. Jager A, Gotz W, Lossdorfer S, Rath-Deschner B, (2009) Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro. J Periodontal Res 45: 246-254.
58. van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, van der Wee-Pals L, et al. (2009) Sclerostin in mineralized matrices and van Buchem disease. J Dent Res 88: 569-574.
59. Tomkinson A, Reeve J, Shaw RW, Noble BS, (1997) The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 82: 3128-3135.
60. Verborgt O, Gibson GJ, Schaffler MB, (2000) Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res 15: 60-67.
61. Kogianni G, Mann V, Noble BS, (2008) Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction. J Bone Miner Res 23: 915-927.
62. Cardoso L, Herman BC, Verborgt O, Laudier D, Majeska RJ, et al. (2009) Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res 24: 597-605.
63. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC, (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102: 274-282.
64. Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, et al. (2004) Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35: 828-835.